Management of Methamphetamine Overdose

Initial Assessment and Stabilization

The American College of Cardiology recommends assessing airway, breathing, circulation, and neurological status immediately in patients with methamphetamine overdose 1
Obtaining an ECG to evaluate for cardiac ischemia, arrhythmias, or other cardiovascular complications is recommended by the American College of Cardiology 2, 1
Cardiac biomarkers, such as troponin, should be considered to assess for myocardial injury, as recommended by the American Heart Association 3, 4

Management of Cardiovascular Complications

The American College of Cardiology recommends administering sublingual nitroglycerin or intravenous calcium channel blockers as first-line therapy for chest pain with suspected coronary vasospasm 2, 5, 6
Avoiding pure beta-blockers is recommended, as they may worsen coronary vasospasm by allowing unopposed alpha-adrenergic stimulation, according to the American College of Cardiology 1, 7
If combined alpha-beta blockers are needed for severe hypertension, they should be used with caution, as recommended by the American College of Cardiology 6, 7

Monitoring and Supportive Care

Patients with ECG changes and normal cardiac biomarkers should be observed in a monitored setting for 24 hours, as most complications occur within this timeframe, according to the American Heart Association 3, 4, 7
A shorter observation period of 9-12 hours with serial troponin measurements at 3, 6, and 9 hours may be appropriate in select cases, as recommended by the American Heart Association 3, 7

Special Considerations and Pitfalls

The American College of Cardiology recommends avoiding beta-blockers in acute methamphetamine intoxication, as they may worsen coronary vasospasm 1, 6, 7
Methamphetamine-related cardiac complications can occur even with normal coronary arteries due to vasospasm, according to the American Heart Association 2, 6

Management of Sympathomimetic Toxidrome Due to Methamphetamine Use

Primary Pharmacological Management

Benzodiazepines alone or in combination with nitroglycerin are the first-line treatment for patients with sympathomimetic toxidrome due to recent methamphetamine use, as recommended by the American Heart Association 8, 9, 10
Administer benzodiazepines as first-line therapy to manage agitation, hypertension, tachycardia, and psychosis in patients with sympathomimetic toxidrome due to methamphetamine use, according to the American College of Cardiology 8, 9, 10
Avoid beta-blockers in patients showing signs of acute methamphetamine intoxication, such as euphoria, tachycardia, and hypertension, due to the risk of potentiating coronary spasm, as advised by the American Heart Association 8, 9, 10

Management of Specific Complications

Cardiovascular Complications

For patients with chest pain and ECG changes, manage as non-ST-elevation acute coronary syndrome (NSTE-ACS) but avoid beta-blockers, as recommended by the American College of Cardiology 8, 9, 10

Special Considerations and Pitfalls

Beta-blockers should be strictly avoided in acute methamphetamine intoxication as they may worsen coronary vasospasm by allowing unopposed alpha-adrenergic stimulation, according to the American Heart Association 8, 9, 10
Patients with a history of methamphetamine use but without signs of acute intoxication can be treated with standard therapies including beta-blockers if indicated, as recommended by the American College of Cardiology 8, 9, 10

Management of Methamphetamine Intoxication

Primary Pharmacological Management

The American College of Cardiology recommends avoiding beta-blockers in patients with signs of acute methamphetamine intoxication, as they may worsen coronary vasospasm through unopposed alpha-adrenergic stimulation 11
Benzodiazepines can be combined with nitroglycerin for better control of hypertension and tachycardia, according to the American College of Cardiology 11

Acute Coronary Syndromes in Methamphetamine Users

Clinical Presentation and Evaluation

The American Heart Association recommends that patients with ST elevation in two leads, even if attributed to previous methamphetamine use, should be sent to the emergency department for urgent evaluation to rule out STEMI, as methamphetamine can cause true myocardial infarction through coronary vasospasm, thrombosis, or accelerated atherosclerosis 12
Methamphetamine causes real acute coronary syndromes by inducing coronary vasospasm, increasing platelet aggregation, and precipitating true STEMI even in patients with normal coronary arteries, with a strength of evidence based on clinical studies 12
ST elevation meeting STEMI criteria demands urgent assessment, with guidelines defining STEMI as ≥0.1 mV (1 mm) ST elevation in at least 2 contiguous limb leads or ≥0.2 mV (2 mm) in 2 contiguous precordial leads, according to the American College of Cardiology 13, 14, 15
Clinical presentation is unreliable, with up to 30% of STEMI patients presenting with atypical symptoms, and methamphetamine users frequently having atypical presentations that can mask true cardiac events, highlighting the need for objective testing 15

Diagnostic Workup and Management

A 12-lead ECG should be obtained immediately upon ED arrival to document ST changes and compare with any prior ECGs, as recommended by the European Society of Cardiology 16, 15
The American Heart Association recommends administering sublingual nitroglycerin or intravenous calcium channel blockers (e.g., diltiazem 20 mg IV) as first-line therapy for suspected coronary vasospasm, with a strength of evidence based on clinical trials 12
Beta-blockers are contraindicated in acute methamphetamine intoxication and may precipitate worse outcomes by allowing unopposed alpha-adrenergic vasoconstriction, according to the American College of Cardiology 12

Coronary Angiography and Observation

Immediate angiography is indicated if ST elevation persists despite nitroglycerin and calcium channel blockers, or if cardiac biomarkers are positive, indicating myocardial injury, as recommended by the American Heart Association 12
Patients with ECG changes and normal initial biomarkers require monitored observation for 9-24 hours, as most methamphetamine-related cardiac complications occur within this timeframe, although this is not directly cited, the recommendation is based on clinical guidelines 15

Management of Severe Sympathomimetic Toxicity with Hyperthermia

Indications for Intubation

The British Journal of Anaesthesia recommends immediate intubation for airway protection and definitive management of life-threatening hyperthermia, as continued agitation despite maximal sedation indicates inability to control metabolic heat production and prevents effective cooling measures 17
The Pediatrics journal indicates that rhabdomyolysis risk is imminent at high temperatures with ongoing muscle activity, leading to renal failure and death, and seizures are likely given the extreme hyperthermia and sympathomimetic toxicity, requiring airway protection 18

Post-Intubation Management

The British Journal of Anaesthesia suggests paralyzing and sedating with continuous benzodiazepine infusion to eliminate muscle heat production, and aggressive cooling measures simultaneously, including chilled saline bolus and external cooling 17
The British Journal of Anaesthesia recommends treating hyperkalaemia with dextrose and insulin, and calcium chloride, and maintaining urine output to prevent myoglobin-induced renal failure with furosemide and mannitol 17

Critical Pitfalls to Avoid

The Pediatrics journal advises against delaying intubation waiting for additional benzodiazepines to work, as every minute at high temperatures causes irreversible organ damage 18
The Circulation journal warns against using beta-blockers, including combined alpha-beta blockers, as they worsen coronary vasospasm through unopposed alpha-adrenergic stimulation in methamphetamine toxicity 19

Expected Outcomes

The Pediatrics journal reports that mortality approaches 11% in severe sympathomimetic toxicity with hyperthermia, with significant morbidity from rhabdomyolysis, renal failure, seizures, and DIC 18
The British Journal of Anaesthesia states that immediate intubation with aggressive cooling and supportive care offers the only chance to prevent these complications and reduce mortality 17

Management of Acute Methamphetamine Intoxication and Cardiovascular Complications

Systematic Screening and Risk Stratification

The American Academy of Family Physicians recommends using a single‑question screen (“How many times in the past year have you used an illegal drug or used a prescription medication for non‑medical reasons?”) because it achieves 90‑100 % sensitivity for detecting substance‑use disorder. 20
If the single question is positive, the Drug Abuse Screening Test‑10 (DAST‑10) should be employed; it identifies abuse or dependence with 90‑100 % sensitivity and 77 % specificity. 20
Methamphetamine carries an intrinsically high risk of self‑harm and harm to others even when used intermittently, distinguishing it from lower‑risk substances. 20
Hazardous use is defined as intermittent methamphetamine use that does not meet formal abuse or dependence criteria but still poses significant health risk because of the drug’s high toxicity. 20
Substance‑abuse criteria (within a 12‑month period) include failure to meet major obligations, use in physically hazardous situations, recurrent legal problems, or continued use despite social/interpersonal problems. 20
Substance dependence requires a more intensive assessment that exceeds the scope of routine primary‑care evaluation. 20

Acute Intoxication Pharmacology

Benzodiazepines are the first‑line pharmacologic therapy for all sympathomimetic manifestations of methamphetamine intoxication (agitation, hypertension, tachycardia, psychosis). The American College of Cardiology emphasizes immediate administration. 21
Beta‑blockers must never be given during acute intoxication because unopposed α‑adrenergic stimulation can precipitate coronary vasospasm and myocardial infarction; this contraindication is supported by both 2013 and 2021 ACC evidence. [21][22]

Cardiovascular Assessment

The American College of Cardiology advises obtaining a 12‑lead electrocardiogram immediately on presentation to detect ischemia, arrhythmia, or ST‑segment elevation. 22
Cardiac biomarkers (troponin) should be measured promptly; methamphetamine can cause true acute coronary syndromes—including STEMI—even in patients with angiographically normal coronary arteries. [21][22]
Up to 70 % of methamphetamine users exhibit abnormal ECG findings, most commonly tachycardia. 22
Acute coronary syndrome occurs in fewer than 10 % of methamphetamine users, and mortality is rare, but clinicians must maintain a high index of suspicion, especially in younger patients with chest pain. 22

Management of Suspected Coronary Vasospasm

First‑line therapy for suspected vasospasm includes sublingual nitroglycerin or intravenous calcium‑channel blockers (e.g., diltiazem 20 mg IV). 21
Patients who meet non‑ST‑elevation ACS criteria should be managed as NSTE‑ACS, but beta‑blockers remain contraindicated during the intoxication phase.

Observation and Disposition

Patients with ECG abnormalities but normal initial troponin should be observed for 9–24 hours, as most meth‑related cardiac events manifest within this window. 21
A shortened 9–12 hour observation with serial troponins at 3, 6, and 9 hours is acceptable in selected low‑risk cases. 21
If clinical status and ECG remain unchanged after 24 hours, discharge is appropriate. 21

Counseling and Follow‑Up

Motivational‑interviewing–based brief counseling reduces the quantity and frequency of methamphetamine use; the American Academy of Family Physicians recommends this approach for hazardous users and those meeting abuse criteria. 20
Hazardous use: provide brief counseling plus ongoing assessment. 20
Substance abuse: deliver brief counseling, negotiate a change plan, arrange close follow‑up, and refer for treatment if use persists. 20
Substance dependence: combine brief counseling with referral for intensive treatment, consider off‑label pharmacotherapy (no FDA‑approved agents), and maintain ongoing support. 20

Common Pitfalls

Clinicians should not dismiss chest pain in methamphetamine users as “anxiety only”; true myocardial infarction can occur via vasospasm, thrombosis, or accelerated atherosclerosis even when coronary arteries appear normal. 22
Combined α‑β blockers (e.g., labetalol) must be avoided during acute intoxication because they still exacerbate coronary vasospasm. 21
Urine drug testing should not be used as the sole diagnostic tool; it is valuable for confirming suspected use, detecting polysubstance exposure, and monitoring treatment response, but not for primary screening. 20